...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Liquidity
4
Jan 21, 2016 06:56PM
5
Jan 21, 2016 07:20PM
1
Jan 22, 2016 09:36AM
1
Jan 22, 2016 05:05PM
4
Jan 22, 2016 05:36PM
4
Jan 22, 2016 06:36PM
4
Jan 24, 2016 11:53AM
Toinv, just my perspective but at the meeting I got the impression that the only thing new to the lawyer regarding an IPO was the reverse takeover of an already listed resource company. As far as 10 to15 years to a drug, I think you are being pessimistic as a trial should be starting very soon and cancer drug development is generally much shorter than many other drugs. I think the presentation says under 4 years so maybe that might be a bit closer. Hopefully!
2
Jan 24, 2016 07:00PM
Share
New Message
Please login to post a reply